Department of Obstetrics and Gynecology, the Center for Women's Health Research, and the Center for Health Promotion and Disease Prevention, University of North Carolina, Chapel Hill, North Carolina; the Department of Public Health Sciences, Henry Ford Hospital, Detroit, Michigan; the Department of Biostatistics & Bioinformatics, the Department of Obstetrics and Gynecology, and the Duke Clinical Research Institute, Duke University, Durham, North Carolina; the Department of Obstetrics and Gynecology, University of Mississippi Medical Center, Jackson, Mississippi, the Division of Reproductive Endocrinology and Infertility and the Division of Health Care Policy and Research, Mayo Clinic, Rochester, Minnesota, the Department of Obstetrics, Gynecology and Reproductive Sciences, University of California, San Francisco, San Francisco, California; the Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, Michigan; the Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts; the Department of Radiology, Georgetown University School of Medicine, Washington, DC; the Fibroid Foundation, Bethesda, Maryland; the Division of Reproductive Endocrinology and Infertility, Department of Obstetrics, Gynecology and Reproductive Biology, Brigham and Women's Hospital, Boston, Massachusetts; the Department of Obstetrics and Gynecology, Inova Fairfax Hospital, Falls Church, Virginia; and the Department of Obstetrics and Gynecology, Augusta University, Augusta, Georgia.
Corresponding author: Wanda K. Nicholson, MD, MPH, UNC-Chapel Hill, Chapel Hill, NC; email: [email protected].
This project was supported by grant number P50HS023418 from the Agency for Healthcare Research and Quality. The content is solely the responsibility of the authors and does not necessarily represent the official views of from the Agency for Healthcare Research and Quality. The funding source has no role in the design or conduct of the study or in the preparation of the manuscript.
Financial Disclosure Elizabeth Stewart received money from Bayer and UpToDate. She received funds from Gynesonics, Welltwigs, Abbvie, Allergan, Med Learning Group. A patent was awarded but no commercial activity for “Methods and Compounds for Treatment of Abnormal Uterine Bleeding 6440445.” Shannon Laughlin-Tommaso received money paid to her from Allergan Pharmaceuticals and UpToDate (fibroid articles). Vanessa Jacoby received money paid to her institution from Acessa Health. Sateria Venable has a financial relationship with Myovant AbbVie. Money has also been paid to his institution from NIH/NICHD, State of Georgia, Yale University, Bayer, ObsEva, AbbVie, Augusta University, and Wayne State University. He is on the Board of Directors and a stock holder for Advanced Reproductive Care and a consultant to Actamax, ZSX Medical, Temple Therapeutics, Seikagaku Corporation, AEGEA, and Trevi Therapeutics. Evan R. Myers has received money paid to him from Allergan, AbbVie, Bayer, and Merck. The other authors did not report any potential conflicts of interest.
Presented at the Society for Reproductive Investigation’s Annual Meeting, March 12–16, 2019, Paris, France, and at the American College of Obstetricians and Gynecologists’ Annual Clinical and Scientific Meeting, May 2–6, 2019, Nashville, Tennessee.
A list of enrolling clinical centers and collaborators can be found in Appendix 1, available online at https://links.lww.com/AOG/B437.
Each author has confirmed compliance with the journal's requirements for authorship.
Peer reviews and author correspondence are available at https://links.lww.com/AOG/B438.
